BeiGene
BGNE
#882
Rank
ยฃ17.80 B
Marketcap
ยฃ159.09
Share price
-0.65%
Change (1 day)
-2.34%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -ยฃ13.93

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -ยฃ12.88. In 2022 the company made an earnings per share (EPS) of -ยฃ15.00 a decrease over its 2021 EPS that were of -ยฃ11.78.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ13.93-7.11%
2022-ยฃ15.0027.35%
2021-ยฃ11.78-19.96%
2020-ยฃ14.7120.81%
2019-ยฃ12.1831.52%
2018-ยฃ9.26417.57%
2017-ยฃ1.79-37.16%
2016-ยฃ2.85158.95%
2015-ยฃ1.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ0.77-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.21-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA